線維性疾患治療薬市場：種類別、治療タイプ別、投与方法別、治療ステージ別、エンドユーザー別-2025-2030年の世界予測

線維性疾患治療薬市場は、2024年には57億8,000万米ドルとなり、2025年には61億3,000万米ドル、CAGR6.46%で成長し、2030年には84億2,000万米ドルに達すると予測されています。

線維性疾患治療市場は、組織の瘢痕化と臓器機能不全を特徴とする複雑な疾患との闘いに重点を置くことを特徴とする、ヘルスケア産業のダイナミックで進化するセグメントです。長年にわたる研究の増加、技術革新、疾病メカニズムの理解の深まりにより、治療アプローチの大幅な進歩に拍車がかかっています。この包括的な分析では、様々な線維化疾患における治療法の臨床的、治療的、経済的な意味を強調しながら、市場に関する確かな洞察に深く切り込んでいます。治療パラダイムを再構築しつつある主要な促進要因、課題、新たな動向を詳細に概観しています。臨床医から意思決定者に至るまで、利害関係者は、続く議論が魅力的で洞察に満ちたものであり、課題的であると同時に変革の機会に満ちている市場情勢を明らかにするものであることを知るであろう。

近年、ヘルスケアシステムは、線維化経路をより効果的に標的とすることを目的とした先端技術や個別化治療法の急速な統合を目の当たりにしてきました。この移行は、規制状況の進化と患者中心のアプローチへの関心の高まりに支えられ、画期的な治療法の進歩への道を開いてきました。慢性線維性疾患の罹患率が上昇を続ける中、市場は技術革新、安全性、臨床的有効性に引き続き重点を置いています。本レポートで紹介する分析は、このようなダイナミクスを詳細に理解することで、利害関係者がこの複雑な分野で展開される機会を十分に活用できるようにするためのものです。

治療パラダイムの転換

線維性疾患治療の状況は、市場を再定義しつつあるいくつかの相互関連的なシフトによって、大きな変革期を迎えています。その最たるものが臨床研究の革新の急増であり、細胞メカニズムや分子プロセスの解明における画期的な進歩が標的治療の開発につながりました。この進化は、治療プロトコルをシフトさせるだけでなく、個々の患者のニーズに密接に沿った、より個別化された治療へのアプローチを促進しています。これと並行して、正確な診断と治療効果のリアルタイム・モニタリングを容易にするデジタル・ヘルス・ソリューションの統合が顕著に推し進められています。

こうした技術革新の採用は、規制当局が承認経路を再検討し再構築することに拍車をかけ、新たな治療薬が厳格な安全性と有効性の基準を満たすことを確実にしています。業界の利害関係者、学術研究者、医療機関の連携が強化されたことで、新たな治療法の市場浸透が加速しており、こうした変化がもたらす変革的なインパクトがさらに強調されています。これらの要因が融合することで、伝統的なパラダイムが、科学的な主導権を持ち、テクノロジーを駆使した治療モデルによって課題される状況が生まれつつあります。ヘルスケアプロバイダーがビッグデータ、AI主導のアナリティクス、ゲノミクスをますます活用するようになるにつれ、患者の転帰の改善と治療プロトコルの洗練がますます具体的になってきています。精密医療と適応的治療戦略に重点を置いたこのパラダイムシフトは、進化し続ける臨床ニーズへの市場の対応を特徴づけるものであり、患者ケアの再構築における継続的イノベーションの重要な役割を強調するものです。

線維性疾患治療市場の主要セグメンテーションインサイト

線維性疾患治療市場を詳細に分析すると、臨床的、技術的、業務的な次元に踏み込んだ多面的なセグメンテーションが明らかになります。タイプに基づくセグメンテーションにより、心線維症、肝線維症、肺線維症、腎線維症などの多様な病態が詳細に調査され、それぞれに固有の課題と治療上の考慮事項が提示されます。これらの区別は、様々な患者ケアのシナリオにおいて介入戦略を調整し、資源配分を最適化するために極めて重要です。

さらに治療の種類別に分類すると、従来の薬物療法、臓器移植術、革新的な酸素療法技術があります。この分類は、治療方法の多様性を強調するものであり、より精緻で的を絞ったアプローチへの臨床実践のシフトを反映しています。投与方法に関する市場セグメンテーションは、吸入、注射、静脈内投与、経口投与、局所投与など、さまざまな臨床承認や患者のコンプライアンス・モデルに対応する幅広い適用技術を示しています。このセグメンテーションは、各手法が示す侵襲性、有効性、コストへの影響のさまざまなレベルを理解するための青写真となります。

さらに、治療ステージ別にセグメンテーションすることで、進行期線維症、早期線維症、末期臓器不全、予防治療が鍵となる前線維症のシナリオを通じたペイシェントジャーニーを特定することができます。このディメンションでは、治療介入の進化を強調し、疾患の進行を抑えるための早期診断と予防的管理の重要性を強調しています。最後に、エンドユーザーに基づくセグメンテーションにより、学術・研究機関、病院、専門クリニックといった主要なヘルスケア環境の役割に焦点が当てられます。これらのセグメントは、最先端の臨床知識の普及、ケアの調整、イノベーションの推進に不可欠です。これらのセグメンテーションを総合すると、市場動向のきめ細かな把握が可能となり、臨床ニーズ、治療イノベーション、ヘルスケア提供モデルの重要な接点が明らかになります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口の高齢化と生活習慣の要因により線維性疾患の罹患率が上昇
    • 世界のヘルスケアインフラの拡大により線維性疾患治療薬へのアクセスが向上
    • 線維症の新規治療法に対する支援的な規制政策と迅速な承認経路
  • 抑制要因
    • 医薬品開発と臨床試験段階に関連する高コストにより、新たな治療への参入が制限される
  • 機会
    • 疾病のモニタリングと治療の遵守を強化するデジタルヘルス技術の統合
    • 線維性疾患に対する精密医療と標的治療アプローチの進歩
  • 課題
    • 線維症の新しい治療法に対する複雑な規制承認プロセスとコンプライアンスの負担
• 市場セグメンテーション分析
  • 治療の種類：線維性疾患の治療薬の消費量の増加
  • エンドユーザー：学術調査機関における線維性疾患治療の初期段階の調査への注目が高まる
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 線維性疾患治療薬市場：タイプ別

• 心臓線維症
• 肝線維症
• 肺線維症
• 腎線維症

第7章 線維性疾患治療薬市場治療の種類別

• 薬物治療
• 臓器移植
• 酸素療法

第8章 線維性疾患治療薬市場投与方法別

• 吸入
• 注射
• 静脈内
• オーラル
• 話題

第9章 線維性疾患治療薬市場治療段階別

• 進行期線維症
• 線維症の初期段階
• 末期臓器不全
• 線維化前（予防治療）

第10章 線維性疾患治療薬市場：エンドユーザー別

• 学術調査機関
• 病院
• 専門クリニック

第11章 南北アメリカの線維性疾患治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の線維性疾患治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの線維性疾患治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Baxter International Inc.
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Ferring Pharmaceuticals Private Limited
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Ipsen Pharma
• Kyorin Pharmaceutical Co., Ltd.
• Mallinckrodt
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis International AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Santen Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

LIST OF FIGURES

• FIGURE 1. FIBROTIC DISEASES TREATMENT MARKET MULTI-CURRENCY
• FIGURE 2. FIBROTIC DISEASES TREATMENT MARKET MULTI-LANGUAGE
• FIGURE 3. FIBROTIC DISEASES TREATMENT MARKET RESEARCH PROCESS
• FIGURE 4. FIBROTIC DISEASES TREATMENT MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. FIBROTIC DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. FIBROTIC DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. FIBROTIC DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. FIBROTIC DISEASES TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY CARDIAC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY LIVER FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY PULMONARY FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY RENAL FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADVANCED-STAGE FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY EARLY-STAGE FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END-STAGE ORGAN FAILURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY PRE-FIBROSIS (PREVENTATIVE TREATMENT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 50. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 51. CANADA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 77. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 78. CHINA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 82. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 83. INDIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 168. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 169. ITALY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 188. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 189. POLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 193. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 194. QATAR FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM FIBROTIC DISEASES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 240. FIBROTIC DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 241. FIBROTIC DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

The Fibrotic Diseases Treatment Market was valued at USD 5.78 billion in 2024 and is projected to grow to USD 6.13 billion in 2025, with a CAGR of 6.46%, reaching USD 8.42 billion by 2030.

The fibrotic diseases treatment market represents a dynamic and evolving segment of the healthcare industry, characterized by its focus on combating complex diseases marked by tissue scarring and organ dysfunction. Over the years, increased research, technological innovations, and a growing understanding of disease mechanisms have spurred significant advancements in treatment approaches. This comprehensive analysis dives deep into robust market insights, emphasizing the clinical, therapeutic, and economic implications of therapies across various fibrotic conditions. It offers a detailed overview of key drivers, challenges, and emerging trends that are reshaping treatment paradigms. Stakeholders, ranging from clinical practitioners to decision-makers, will find the ensuing discussions engaging and insightful, revealing a market landscape that is both challenging and ripe with transformative opportunities.

In recent times, healthcare systems have witnessed rapid integration of advanced technologies and personalized treatment regimes aimed at targeting fibrotic pathways more effectively. This transition, supported by evolving regulatory landscapes and an increased focus on patient-centric approaches, has paved the way for groundbreaking therapeutic advancements. As the incidence of chronic fibrotic conditions continues to rise, the market's focus on innovation, safety, and clinical efficacy remains paramount. The analysis presented in this report is designed to offer a granular understanding of these dynamics, ensuring that every stakeholder is well-equipped to navigate and capitalize on the unfolding opportunities in this intricate field.

Transformative Shifts in the Treatment Paradigm

The landscape of fibrotic diseases treatment is experiencing a period of significant transformation, driven by several interconnected shifts that are redefining the market. Foremost among these is the surge in clinical research innovations, where breakthroughs in understanding cellular mechanisms and molecular processes have led to the development of targeted therapies. This evolution is not only shifting treatment protocols but also fostering a more personalized approach to care that is closely aligned with individual patient needs. In parallel, there has been a notable push towards integrating digital health solutions, which facilitate precise diagnosis and real-time monitoring of treatment efficacy.

The adoption of these innovations has spurred regulatory bodies to revisit and reshape approval pathways, ensuring that emerging therapies meet stringent safety and efficacy standards. Enhanced collaboration between industry stakeholders, academic researchers, and medical institutions has accelerated market penetration of novel interventions, further underscoring the transformative impact of these shifts. The convergence of these factors is creating a landscape where traditional paradigms are being challenged by scientifically driven, technology-enabled treatment models. As healthcare providers increasingly leverage big data, AI-driven analytics, and genomics, the promise of improved patient outcomes and refined treatment protocols becomes ever more tangible. This paradigm shift, marked by its emphasis on precision medicine and adaptive treatment strategies, characterizes the market's response to ever-evolving clinical needs and underscores the vital role of continuous innovation in reshaping patient care.

Key Segmentation Insights in the Fibrotic Diseases Treatment Market

An in-depth analysis of the fibrotic diseases treatment market reveals a multifaceted segmentation that dives into clinical, technological, and operational dimensions. The segmentation based on type provides a detailed exploration of diverse conditions such as cardiac fibrosis, liver fibrosis, pulmonary fibrosis, and renal fibrosis, each presenting unique challenges and therapeutic considerations. These distinctions are crucial for tailoring intervention strategies and optimizing resource allocation in various patient care scenarios.

Further segmentation by treatment type distinguishes between conventional medication, organ transplantation procedures, and innovative oxygen therapy techniques. This classification underscores the diversity in treatment modalities, reflecting shifts in clinical practices towards more refined and targeted approaches. The market's segmentation regarding administration methods-ranging from inhalation, injection, intravenous, oral, to topical methods-illustrates the wide range of application techniques that cater to different clinical approvals and patient compliance models. This segmentation serves as a blueprint to understand the varying levels of invasiveness, efficacy, and cost implications that each method presents.

Additional segmentation by treatment stage identifies patient journeys through advanced-stage fibrosis, early-stage fibrosis, end-stage organ failure, and pre-fibrosis scenarios where preventative treatment is key. This dimension highlights the evolution of therapeutic interventions and emphasizes the importance of early diagnosis and proactive management in mitigating disease progression. Finally, segmentation based on the end user brings into focus the roles of key healthcare settings such as academic and research institutes, hospitals, and specialty clinics. These segments are integral in the dissemination of cutting-edge clinical knowledge, the coordination of care, and the drive towards innovation. Collectively, these segmentation insights provide a granular understanding of market trends, revealing critical intersections between clinical need, treatment innovation, and healthcare delivery models.

Based on Type, market is studied across Cardiac Fibrosis, Liver Fibrosis, Pulmonary Fibrosis, and Renal Fibrosis.

Based on Treatment Type, market is studied across Medication, Organ Transplantation, and Oxygen Therapy.

Based on Administration Method, market is studied across Inhalation, Injection, Intravenous, Oral, and Topical.

Based on Treatment Stage, market is studied across Advanced-Stage Fibrosis, Early-Stage Fibrosis, End-Stage Organ Failure, and Pre-Fibrosis (Preventative Treatment).

Based on End User, market is studied across Academic & Research Institutes, Hospitals, and Specialty Clinics.

Key Regional Insights: Global Perspectives on Market Dynamics

The global fibrotic diseases treatment market demonstrates significant regional variations, each contributing unique insights into market trends and healthcare innovations. In the Americas, robust healthcare infrastructure and an environment that fosters extensive clinical research have accelerated the adoption of advanced treatment modalities. This region is characterized by its high healthcare spending, progressive regulatory frameworks, and the presence of leading clinical research institutions that collectively drive accelerated market maturity. The regional focus on patient-centric care and widespread insurance coverage further amplify the adoption of targeted treatment strategies and novel intervention techniques.

Across Europe, the Middle East, and Africa, diverse factors shape the market dynamics, ranging from varied economic landscapes to significant regulatory heterogeneity. This collection of regions presents an intriguing mix of mature healthcare systems alongside rapidly evolving medical practices. The emphasis on disease prevention and early intervention, coupled with a strong push towards technology-driven diagnostics, is fostering an environment ripe for innovation. Moreover, strategic partnerships across academic institutions and pharmaceutical companies in these regions have resulted in rapid knowledge transfer and the expedited introduction of efficacious treatment options to clinical practice.

The Asia-Pacific region stands out for its rapid expansion of healthcare infrastructure, driven by burgeoning economies and increasing investments in medical research. With a growing middle class and heightened awareness about chronic diseases, this region has emerged as a critical hub for clinical trials and translational research in fibrotic diseases. The blend of traditional and modern therapeutic approaches has not only diversified treatment protocols but also positioned the market for sustained growth. Region-specific initiatives aimed at healthcare democratization and improved accessibility have further catalyzed the adoption of innovative treatment models. Collectively, these regional insights reveal a complex, yet highly dynamic, global market landscape where local innovations meet global best practices to drive comprehensive advancements in fibrotic diseases treatment.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Insights from Leading Market Players

The competitive landscape of the fibrotic diseases treatment market is defined by contributions from an array of leading companies that have consistently driven innovation and market growth. Industry frontrunners such as AbbVie Inc., Amgen Inc., Baxter International Inc., and Biogen Inc. have been instrumental in pioneering advancements in therapeutic modalities and enhancing patient care outcomes. Major players including Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, and Eli Lilly and Company have leveraged extensive research and development pipelines to introduce groundbreaking treatment options that address complex fibrotic pathways.

This landscape is further enriched by companies like Ferring Pharmaceuticals Private Limited, Gilead Sciences, Inc., and GlaxoSmithKline plc, which have integrated cutting-edge technology and robust clinical trials into their treatment portfolios. Collaboration and strategic investments by Ipsen Pharma and Kyorin Pharmaceutical Co., Ltd. have also significantly contributed to evolving treatment protocols and expanding drug accessibility. The market's momentum is additionally amplified by the initiatives from Mallinckrodt, Merck & Co., Inc., and Mitsubishi Tanabe Pharma Corporation, whose concerted efforts in clinical research have paved the way for pioneering therapeutic interventions.

Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Sanofi S.A. continue to redefine industry standards through innovative research, clinical excellence, and strategic partnerships. The impact of Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A. further underscores a collaborative commitment to advancing treatment paradigms. These industry leaders, with their expansive global networks and emphasis on precision medicine, have not only enriched the competitive landscape but have also set a high benchmark for quality and efficacy in fibrotic diseases treatment. Their contributions, grounded in rigorous clinical research and sustained investment in innovation, continue to shape the market's trajectory and highlight the importance of an integrated approach in addressing the multifaceted challenges associated with fibrotic disease management.

The report delves into recent significant developments in the Fibrotic Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Baxter International Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Ferring Pharmaceuticals Private Limited, Gilead Sciences, Inc., GlaxoSmithKline plc, Ipsen Pharma, Kyorin Pharmaceutical Co., Ltd., Mallinckrodt, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A.. Actionable Recommendations for Industry Leaders

Industry leaders must adopt a proactive strategy that blends clinical innovation with market responsiveness to capitalize on emerging opportunities in fibrotic diseases treatment. First, enhancing investment in research and development is essential, with particular emphasis on next-generation diagnostic tools and personalized treatment regimens. Leaders should leverage advanced analytics to gain deeper insights into patient profiles and disease progression dynamics, effectively tailoring treatment protocols to improve clinical outcomes. Embracing information technology to integrate real-time data from clinical trials and patient feedback can further refine product development and ensure rapid iteration of therapeutic strategies.

Moreover, forging collaborative partnerships with academic institutions and research organizations will facilitate the sharing of critical knowledge and accelerate the translation of scientific breakthroughs into market-ready therapies. By establishing dedicated innovation hubs and cross-functional teams, organizations can better navigate the complex regulatory environment and ensure that their products meet both market expectations and stringent safety standards.

In addition, expanding geographical reach through strategic regional alliances holds significant promise. The juxtaposition of mature and emerging markets offers periods of competitive advantage that can be harnessed by tailoring solutions to region-specific needs. Industry leaders must also focus on robust market education programs to raise awareness about the latest advancements in fibrotic diseases treatment, thereby driving both demand and patient engagement. Comprehensive training for healthcare practitioners on the efficacy, mechanism of action, and safety profiles of new treatments will be critical in building trust and accelerating adoption across clinical settings.

Finally, companies must remain agile in responding to evolving market trends. This involves continuous monitoring of competitive dynamics, regulatory shifts, and technological advancements. A dynamic approach to risk management-coupled with strategic resource allocation and consistent stakeholder engagement-can help navigate uncertainties while ensuring sustained growth and innovation in this rapidly evolving landscape.

Conclusion: Synthesizing Critical Market Insights

The overall analysis of the fibrotic diseases treatment market uncovers an intricate tapestry of innovation, regional dynamics, and competitive collaboration. Through a detailed exploration of clinical segmentation, it becomes evident that diverse treatment pathways are tailored to address the distinct challenges presented by various fibrotic conditions. By aligning patient-centric treatment approaches with modern delivery methods, the market is making significant strides towards improving therapeutic outcomes and enhancing the quality of life for affected individuals.

The transformative shifts in the treatment landscape highlight the increasing importance of precision medicine, leveraging technological advancements such as advanced diagnostic tools, AI-driven analytics, and digital health integrations. These shifts not only ensure greater clinical accuracy but also pave the way for earlier interventions, thereby mitigating disease progression and reducing long-term healthcare costs. The integration of such innovations into clinical practice is critical for managing both early-stage interventions and late-stage treatment challenges.

Furthermore, a global perspective reveals that while mature markets in the Americas and Europe, Middle East & Africa benefit from established healthcare infrastructures and research capabilities, the Asia-Pacific region is rapidly emerging as a pivotal market with burgeoning opportunities for growth. The seamless blend of innovative treatment technologies and evolving healthcare policies across these regions underscores a unified drive towards holistic and comprehensive care.

In summary, the convergence of detailed segmentation insights, regional market analyses, and a robust competitive landscape consolidates the understanding of current trends and future directions in the fibrotic diseases treatment market. Strategic investments, agile market approaches, and an unwavering commitment to clinical excellence will remain the cornerstones of growth, innovation, and sustained market success.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of fibrotic diseases due to aging populations and lifestyle factors
    • 5.1.1.2. Expansion of global healthcare infrastructure improving access to fibrotic diseases treatment
    • 5.1.1.3. Supportive regulatory policies and expedited approval pathways for novel fibrotic therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with drug development and clinical trial phases limiting new treatment entries
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of digital health technologies enhancing disease monitoring and treatment adherence
    • 5.1.3.2. Advancements in precision medicine and targeted treatment approaches for fibrotic conditions
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory approval processes and compliance burdens for novel fibrotic treatment solutions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Rising consumption of medications for the treatment of fibrotic conditions
  • 5.2.2. End User: Increasing focus on the early-stage research of fibrotic diseases treatments in academic & research institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Fibrotic Diseases Treatment Market, by Type

• 6.1. Introduction
• 6.2. Cardiac Fibrosis
• 6.3. Liver Fibrosis
• 6.4. Pulmonary Fibrosis
• 6.5. Renal Fibrosis

7. Fibrotic Diseases Treatment Market, by Treatment Type

• 7.1. Introduction
• 7.2. Medication
• 7.3. Organ Transplantation
• 7.4. Oxygen Therapy

8. Fibrotic Diseases Treatment Market, by Administration Method

• 8.1. Introduction
• 8.2. Inhalation
• 8.3. Injection
• 8.4. Intravenous
• 8.5. Oral
• 8.6. Topical

9. Fibrotic Diseases Treatment Market, by Treatment Stage

• 9.1. Introduction
• 9.2. Advanced-Stage Fibrosis
• 9.3. Early-Stage Fibrosis
• 9.4. End-Stage Organ Failure
• 9.5. Pre-Fibrosis (Preventative Treatment)

10. Fibrotic Diseases Treatment Market, by End User

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Fibrotic Diseases Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Fibrotic Diseases Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Fibrotic Diseases Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Mediar Therapeutics secures global licensing with Lilly in a USD 99 million upfront deal to expand its treatment pipeline for fibrotic diseases
  • 14.3.2. Relation partners with GSK for accelerating breakthrough fibrotic disease and osteoarthritis treatments
  • 14.3.3. Madrigal Pharmaceutical secures accelerated FDA approval for Rezdiffra as a groundbreaking noncirrhotic NASH treatment
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Baxter International Inc.
• 4. Biogen Inc.
• 5. Boehringer Ingelheim International GmbH
• 6. Bristol-Myers Squibb Company
• 7. Eli Lilly and Company
• 8. Ferring Pharmaceuticals Private Limited
• 9. Gilead Sciences, Inc.
• 10. GlaxoSmithKline plc
• 11. Ipsen Pharma
• 12. Kyorin Pharmaceutical Co., Ltd.
• 13. Mallinckrodt
• 14. Merck & Co., Inc.
• 15. Mitsubishi Tanabe Pharma Corporation
• 16. Novartis International AG
• 17. Pfizer Inc.
• 18. Regeneron Pharmaceuticals, Inc.
• 19. Sanofi S.A.
• 20. Santen Pharmaceutical Co., Ltd.
• 21. Takeda Pharmaceutical Company Limited
• 22. Teva Pharmaceutical Industries Ltd.
• 23. UCB S.A.